Each May, during Lupus Awareness Month, advocates, researchers, and patients push for greater visibility around a disease that disproportionately affects women of color while remaining widely misunderstood and underfunded. Systemic lupus erythematosus, commonly known as lupus, is a chronic autoimmune disease that can damage the skin, joints, kidneys, heart, and brain. Although anyone can develop lupus, Black, Hispanic, Indigenous, and Asian communities face significantly higher risks and often experience more severe complications.

According to the Centers for Disease Control and Prevention, Black women are two to three times more likely than white women to develop lupus and are more likely to experience severe disease, kidney complications, and earlier death. The CDC also reports that Black people with lupus die at younger ages, on average more than a decade earlier than white patients.

Despite those disparities, Black and brown patients continue to be underrepresented in lupus clinical trials, a gap many researchers and advocacy organizations say has slowed progress toward equitable treatment and care. Clinical trials are essential to developing new medications and understanding how treatments work across different populations. Without representative participation, experts warn that therapies may not fully reflect the needs or biological realities of the communities most affected by the disease.

Researchers say the issue is not simply about awareness. Structural barriers including medical mistrust, unequal access to specialty care, financial strain, transportation challenges, and a long history of racial inequities in healthcare all contribute to low participation rates. Many patients are never informed about clinical trial opportunities in the first place.

A recent study published in Lupus Science & Medicine found that Black patients remain significantly underrepresented in lupus clinical trials even though they experience higher disease severity and worse outcomes. Researchers noted that only about 14 percent of participants in lupus randomized controlled trials were Black patients, despite Black Americans accounting for a far larger share of lupus cases nationwide. (lupus.bmj.com)

The lack of inclusion has serious implications for treatment development. Some lupus medications may work differently across populations due to genetic, environmental, and social factors. Experts say broader representation in research could help scientists better understand how the disease progresses in different communities and lead to more effective therapies.

The National Institutes of Health and the CDC have both expanded lupus research efforts in recent years, funding registries and studies focused on health disparities and social determinants of health. The CDC currently supports multiple lupus registries across the United States aimed at understanding who develops the disease and how race, geography, and access to care affect outcomes.

Still, many advocates argue progress has been too slow for patients already navigating years of delayed diagnoses and inadequate support. Lupus symptoms often mimic other illnesses, making diagnosis difficult. Patients frequently report being dismissed by healthcare providers or waiting years before receiving answers. For women of color, those delays can be even longer due to racial bias and gaps in healthcare access.

Community voices online have increasingly reflected those frustrations. In discussions shared on forums like Reddit, patients describe struggling to find knowledgeable doctors, feeling isolated during diagnosis, and searching for support systems that understand both the medical and cultural realities of living with lupus. Some Black women with lupus have also spoken openly about feeling invisible within broader healthcare conversations despite carrying some of the highest disease burdens. (Reddit)

Advocates say Lupus Awareness Month is not only about visibility but accountability. They argue that raising awareness must include investing in equitable research, expanding access to rheumatology care, improving physician education, and ensuring patients of color are included in the future of treatment development.

As researchers continue searching for better therapies and, eventually, a cure, many patients and advocates believe meaningful progress will depend on whether the healthcare system finally addresses the disparities that have shaped lupus care for decades. For communities already carrying the heaviest burden of the disease, representation in clinical trials is increasingly being viewed not as an option, but as a matter of health equity and survival.